AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
AZD7268 Single Ascending Dose Study in Healthy Japanese Subjects
- First Posted Date
- 2009-06-03
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT00912353
- Locations
- 🇺🇸
Research Site, Gelndale, California, United States
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
Phase 1
Completed
- Conditions
- Primary Myelofibrosis (PMF)Post-Polycythaemia VeraEssential Thrombocythaemia Myelofibrosis
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2017-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00910728
- Locations
- 🇫🇷
Research Site, Villejuif Cedex, France
AZD9056 Relative Bioavailability Study
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: AZD9056 formulation Phase III 50 mg (T)Drug: AZD9056 formulation Phase IIb 50 mg (R)Drug: AZD9056 formulation Phase III 200 mg (T)Drug: AZD9056 formulation Phase IIb 200mg (R)
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2009-07-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00908934
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT00908271
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E
- First Posted Date
- 2009-05-22
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00907400
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
AZD0837 Extended Release (ER) Japan Study
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2009-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00904800
- Locations
- 🇯🇵
Research Site, Kagoshima, Japan
Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00905333
- Locations
- 🇧🇷
Research Site, Americana, Brazil
Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-05-19
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00904176
- Locations
- 🇺🇸
Pra International, Lenexa, Kansas, United States
Study to Investigate Safety, Tolerability and Pharmacokinetics With Single and Multiple Ascending Doses of AZD1446
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2009-10-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00902993
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users
Phase 1
Completed
- Conditions
- Recreational CNS Depressant Use
- Interventions
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2009-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00902772
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada